Targets › GCGR
18 programs from 16 companies in 66 trials: 34 Phase 3, 18 Phase 1, 9 Phase 2, 5 Phase 4; Metabolic and endocrine, Cardiovascular, Gastroenterology; next expected readout Nov 2026.
G protein-coupled receptor for glucagon that plays a central role in the regulation of blood glucose levels and glucose homeostasis. Regulates the rate of hepatic glucose production by promoting glycogen hydrolysis and gluconeogenesis. (UniProt, P47871)
Open in Phaseline: the race on GCGR, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Joslin Diabetes Center | Glucagon Glucagon receptor agonist | GCGR | Phase 4 | Hypoglycemia | Jan 2027 |
| Steno Diabetes Center Copenhagen | Glucagon Glucagon receptor agonist | GCGR | Phase 4 | Type 1 Diabetes Mellitus | May 2027 |
| China National Center for Cardiovascular Diseases | Mazdutide Dual GLP-1/glucagon receptor agonist | GLP1R, GCGR | Phase 4 | Obesity & Overweight | Dec 2027 |
| West China Hospital | Mazdutide GLP-1/GCG receptor dual agonist | GLP1R, GCGR | Phase 4 | Metabolic Dysfunction-Associated Steatohepatitis | Feb 2029 |
| Eli Lilly | Retatrutide Glucagon receptor agonist; Glucagon-like peptide 1 receptor agonist; Gastric inhibitory polypeptide receptor agonist | GCGR, GLP1R, GIPR | Phase 3 | Obesity; Type 2 Diabetes; Diabetes Mellitus, Type 2; Atherosclerotic Cardiovascular Disease (ASCVD) … | Nov 2026 |
| AstraZeneca | Elecoglipron Dipeptidyl peptidase-4 (DPP-4) inhibitor | DPP4, GCK, GCGR | Phase 3 | Obesity; Type 2 Diabetes Mellitus; Weight Management; Heart Failure With Preserved Ejection Fraction (HFpEF) … | Nov 2026 |
| Boehringer Ingelheim | Survodutide Glucagon-like peptide 1 receptor agonist; Glucagon receptor agonist | GLP1R, GCGR | Phase 3 | Type 2 Diabetes; Metabolic Dysfunction Associated Steatohepatitis; Metabolic Dysfunction Associated Steatohepatitis (MASH); Healthy … | Dec 2026 |
| Eli Lilly | Eloralintide (LY3841136) GLP-1/GCG dual receptor agonist | GLP1R, GCGR | Phase 3 | Overweight; Obesity; Sleep Apnea, Obstructive; Osteoarthritis … | Dec 2026 |
| Altimmune | Pemvidutide GLP-1 and glucagon receptor dual agonist | GLP1R, GCGR | Phase 3 | Metabolic Dysfunction-Associated Steatohepatitis (MASH); Alcohol-associated Liver Disease | Sep 2027 |
| AstraZeneca | AZD6234 (Lenbelintide) Glucagon receptor agonist | GCGR | Phase 3 | Obesity or Overweight | Aug 2028 |
| Roche | Petrelintide Dual GLP-1 and glucagon receptor agonist | GLP1R, GCGR | Phase 3 | Obesity or Overweight | Oct 2028 |
| The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Mazdutide (IBI362) Triple GLP-1/GIP/glucagon receptor agonist | GLP1R, GIPR, GCGR | Phase 3 | Dementia, Mild | Aug 2029 |
| Hudson Biotech | Retatrutide (LY3437943) Glucagon receptor agonist; Glucagon-like peptide 1 receptor agonist; Gastric inhibitory polypeptide receptor agonist | GCGR, GLP1R, GIPR | Phase 2 | Obesity | Mar 2027 |
| Hanmi Pharmaceutical Company | HM15136 Glucagon analog | GCGR | Phase 2 | Congenital Hyperinsulinism | May 2027 |
| City of Hope Medical Center | Allogenic Human Islet Cells Intraportal infusion of insulin-producing pancreatic islet cells for metabolic restoration | INSULIN, GCGR | Phase 2 | Type 1 Diabetes Mellitus; Diabetes Mellitus, Type 1 | Aug 2027 |
| University of California, San Diego | Volagidemab Glucagon receptor inhibitor | GCGR | Phase 2 | Type 1 Diabetes | Jan 2028 |
| AdventHealth Translational Research Institute | Glucagon Glucagon receptor agonist | GCGR | Phase 1 | Obesity | Dec 2026 |
| The University of Texas Health Science Center at San Antonio | Volagidemab (REMD-477) Glucagon receptor inhibitor | GCGR | Phase 1 | Non-Diabetic | May 2030 |
Obesity (17) Obesity or Overweight (6) Type 2 Diabetes Mellitus (5) Overweight (4) Type 2 Diabetes (2) Healthy Participants (2) Hypoglycemia (2) Healthy (2) Type 1 Diabetes Mellitus (2) Type 1 Diabetes (2) Diabetes Mellitus, Type 2 (1) Atherosclerotic Cardiovascular Disease (ASCVD) (1)
protein or peptide (10), small molecule (5), mixed (2)
Eli Lilly (2) AstraZeneca (2) Joslin Diabetes Center (1) Boehringer Ingelheim (1) Hanmi Pharmaceutical Company (1) City of Hope Medical Center (1) The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (1) University of California, San Diego (1) AdventHealth Translational Research Institute (1) Altimmune (1) Steno Diabetes Center Copenhagen (1) West China Hospital (1) Roche (1) China National Center for Cardiovascular Diseases (1) The University of Texas Health Science Center at San Antonio (1) Hudson Biotech (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.